Skip to main content
Tuesday, November 17, 2026Nov 17

North America trade pact deals rare setback to Big Pharma

FILE - In this June 15, 2018, file photo, pharmaceuticals are seen in North Andover, Mass. Feeling a new urgency as the impeachment probe advances, the White House is ramping up its push to get a bill through Congress that curbs prescription drug costs. President Donald Trump's top domestic policy adviser says the effort has advanced beyond anything seen in years even as he acknowledges the "current complications." (AP Photo/Elise Amendola, file)
FILE - In this June 15, 2018, file photo, pharmaceuticals are seen in North Andover, Mass. Feeling a new urgency as the impeachment probe advances, the White House is ramping up its push to get a bill through Congress that curbs prescription drug costs. President Donald Trump's top domestic policy adviser says the effort has advanced beyond anything seen in years even as he acknowledges the "current complications." (AP Photo/Elise Amendola, file)

A revamped North American trade deal nearing passage in Congress gives both the White House and Democrats a chance to claim victory and offers farmers and businesses clearer rules governing the vast flow of goods among the United States, Canada and Mexico.

But the pact leaves at least one surprising loser: the pharmaceutical industry, a near-invincible lobbying powerhouse in Washington.

To satisfy House Democrats, the Trump administration removed a provision that would have given the makers of ultra-expensive biologic drugs 10 years of protection from less expensive knockoffs. Democrats opposed what they called a giveaway to the industry that could have locked in inflated prices by stifling competition. Top examples of the injected drugs made from living cells include medications to fight cancer and immune disorders such as rheumatoid arthritis.

“This is one of the first times we’ve actually seen pharma lose,” said Rep. Earl Blumenauer, an Oregon Democrat who leads a subcommittee on trade. “They have a remarkable track record because they are a huge political force. They spend lots of money on lobbying, on advertising, on campaign contributions. But we held firm, and we won on all counts.”

The removal of the provision also helped illustrate just how potent a political issue sky-high drug prices have become. It was a reminder, too, that President Donald Trump repeatedly pledged to work to lower drug prices.